Member Info for hopeabound

Here it is with a link and without spaces.

Valuation of Metir at this early stage of the Microtox® and CTM platform rollout is inherently challenging.

However, we note that the legacy Modern Water business historically generated annual revenues in the £3–4m range. Under a scenario in which the Company successfully scales its installed base and increases the contribution from higher-margin revenues, particularly consumables, QuickChek® SRB kits and CTM deployments, we believe that revenues could expand meaningfully over the medium term into the mid -teens of millions (GBP), with a corresponding expansion in the group gross margin. We have built a model using our own assumptions, not guided by Metir management. On this basis, and subject to the assumptions set out in our model (including a conservative 80% risk adjustment to the figure our DCF produces), we derive a DCF-derived near term fair value of 2.5p per share.

https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/697834f1-eb14-6769-0b7d-93c278ceded2/Metir_Report_17th_June_2026_SHv4_Final.pdf

Sorry about the spaces

Valuation of Metir at this early stage of the Microtox® and CTM platform rollout is inherently challenging.

However, we note that the legacy Modern Water business historically generated annual revenues in the £3–4m

range. Under a scenario in which the Company successfully scales its installed base and increases the

contribution from higher-margin revenues, particularly consumables, QuickChek® SRB kits and CTM

deployments, we believe that revenues could expand meaningfully over the medium term into the mid -teens of

millions (GBP), with a corresponding expansion in the group gross margin. We have built a model using our own

assumptions, not guided by Metir management. On this basis, and subject to the assumptions set out in our model

(including a conservative 80% risk adjustment to the figure our DCF produces), we derive a DCF-derived nearterm fair value of 2.5p per share.

CPAI dead, and yet here you are with your one life on Earth, spending it on a forum where you are not invested. Do yourself a favour Macintyre.

Good interview. Thanks for the link.

The presentation looks good. The product, practical and what authors want. We will see how this gets promoted and picked up. But it does look enticing.

And yesterday in reference to Author Jayne Lytel wrote: "Our product finally launched!"

Chief AI Architect @ capMedia Inc. | Author of 𝑅𝑢𝑛 𝐹𝑟𝑜𝑚 𝑆𝑢𝑛𝑑𝑎𝑦 | Cybersecurity Strategy & AI Enablement | National Press Club Vivian Awardee

15h •

Top notch. Great innovative company with multiple commercial possibilities now coming into view. This is my expected favourite to making me the most over the next few years. And should do well SP wise over the next 12 months too.

Yup, good to see. Expecting good things over the next 12 months.

Heading into a good place now. Restructure complete. Good times ahead.

A much needed RNS and an inflection point. Timing is everything, I got this wrong early doors but any worries have faded for the time being. The rise will be consistent over the rest of the week I would think.

An unexpected and very pleasant RNS. Laying the groundwork for expansion. It's a great company to be invested in for the work they are doing. Vital. The Iranian war has been troubling given Metir's presence there, so expansion outside of the Middle East is good to hear. Once the conflict ends, then this should ease worries regarding civilian infrastructure threats from America and the Iranian threats if that happens.

Indeed. The regional (at the moment) war from Metir perspective is a challenge. Good the money came in. Great they are funded. Felt like we were close towards moving to a new phase and beig along-term hold, hopefully nothing has changed. Hoping this stops soon or horrendous outcomes will follow.

If this list is anytning to go by - then it may indicate what we can expect incoming at some point as part of the longevity element of CPAI.

https://www.linkedin.com/posts/ronjonnag_stanfordgenetics-department-ai-longevity-share-7445514607919718400-rq8X/

Final Syllabus

Week 1: April 2nd : Course overview; The body aging process, aging vaccines. Cartilage and muscle aging.

Prof. Ronjon Nag, PhD, Stanford: The body aging process, aging vaccines.

Prof Helen Blau, Stanford: Cartillage and Muscle aging:

Week 2: April 9th: Science of Love and age. Bladder and prostate aging

Prof Ronjon Nag, Stanford The science of love and aging: Speaker: Anne Lindsfors

Daniel Garrett Wong, MD Bladder and prostate aging

Week 3: April 16th: Skin and Hair Aging. The Role of Thymus and aging

Prof Anne Chang, Stanford: Skin and Hair Aging

Prof Katja Weinacht, Stanford, The role of the Thymus and Aging

Week 4: April 23rd: The new map of life. Eating and aging.

Prof Laura Carstensen, Stanford, The new map of life

Dalia Perelman, nutritionist, Stanford: Eating and aging

Week 5: April 30th: How to make a vaccine for aging. Ovarian aging

Prof Jay Rajadas, Stanford: Brain Aging Reversal

Prof. Josh Johnson, University of Colorado at Denver, Ovarian aging

Week 6: May 7: Aging of the brain. Aging of bones.

Christin Glorioso, PhD, CEO Neuroage: Aging of the brain.

Prof. Michael Fredericson, MD, Stanford: Aging of bones and osteoarthritic aging

Week 7: May 14: Lung Aging

Prof. Tushar Desai, Lung Aging

Niki Santo, CEO, Swaza.life: New oxygen therapeutics

Week 8: May 21sth: Wound healing aging. Heart aging

Dr. Artem Trotsyuk, PhD Stanford: Wound healing

Prof Francois Haddad, Heart aging

Week 9: May 28th: Genetic Expression and Aging

What happens to DNA expression as we get older

Prof. Michael Snyder, Stanford

Week 10: Student Presentations

Goodlife. I would go along with that. Could be a more dynamic presentation but strip that awy, what he esaid was clear and fine. Traders will move on, it is clearly a long term hold. Has been a while since some news, so it will be nice when that starts rolling in again. Hopefully, investors start coming in and the project development moves ot the commericalisation stage. Not expecting much in rise back up for the next 6 months. Hopefully, I am wrong but then will see.

New not news

Interesting.

Https://www.theguardian.com/environment/2026/feb/14/race-to-find-source-of-carcinogenic-chemical-pfos-polluting-cumbria-and-lancashire-waters

'A string of toxic pollution hotspots has been uncovered across Cumbria and Lancashire, with high levels of the banned cancer-causing “forever chemical” Pfos detected in rivers and groundwater at 25 sites.

The contamination, spread across a large area, was uncovered by Watershed Investigations and the Guardian after a freedom of information request revealed high concentrations of Pfos in Environment Agency samples taken in January 2025.'

What this tells me, is that Metir tech could find this stuff out quickly, and action can be taken promptly when detected. Looking forward to the news from this company over the course of the next 12 months

I have 400,500

In their January Trading update they said: Metir is developing what it believes could be significant future revenue streams from new technologies, including its proprietary mobile PFAS testing technology with Swansea University, and progressing towards completion of the Cryptosporidium project in 2026 with Aptamer Group plc for deployment of a commercial real-time continuous Pathogen Detector. The next few years will be transformative for this company.